Pharma BD Deal Intelligence
Alexion (AstraZeneca Rare Disease) closed an exclusive global collaboration and license agreement with Switzerland's Neurimmune in March 2022 for NI006 — now the human monoclonal antibody cliramitug (development code ALXN2220) — a first-in-class amyloid depleter for transthyretin amyloid cardiomyopathy (ATTR-CM). Neurimmune received $30M upfront with up to $730M in development, regulatory and commercial milestones plus tiered low-to-mid teen royalties ($760M total potential), and retained the ongoing Phase 1b study before Alexion took over development. The depleter mechanism aimed to clear existing cardiac amyloid, differentiating it from Pfizer's tafamidis stabilizer and the RNA silencers from Alnylam/BridgeBio. The thesis has since been de-risked: Phase 1 results (NI006-101, NCT04360434) published in NEJM in May 2023 showed substantial cardiac ATTR depletion with no drug-related serious adverse events, and Alexion advanced the asset into the registrational Phase 3 DepleTTR-CM trial (NCT06183931; initiated January 2024, ~1,181 patients, primary completion estimated 2027), now active and no longer recruiting. In December 2025 the companies expanded the partnership to a second fibril depleter, NI009 for AL amyloidosis (a separate agreement worth up to $780M in milestones plus royalties).